01801 News & Events

Innovent Biologics announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D, B-cell maturation antigen, and CD3 for the treatment of relapsed or refractory multiple myeloma, in an oral presentation at the 2025 American Society of Hematology Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile. Despite the relatively short follow-up duration, IBI3003 has shown encouraging efficacy signals, particularly in high-risk patients with extramedullary disease or those who have previously received anti-BCMA and/or anti-GPRC5D targeted therapies. Encouraging efficacy was observed with a median follow-up of 3.25 months: Among patients treated with greater than or equal to120 undefined/kg, the overall response rate was 83.3%, including 4 cases of stringent complete response, 7 cases of very good partial response, and 9 cases of partial response. Among patients treated with greater than or equal to120 undefined/kg, the ORR was 80% in 10 patients with EMD and 77.8% in 9 patients who had previously received anti-BCMA and/or anti-GPRC5D therapies. Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing testing, the minimal residual disease negativity rate was 100%

Innovent Biologics announced that it has been successfully added as a constituent stock of the Hang Seng Index, HSI, following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representing Hong Kong's core assets. "This milestone makes Innovent the first company that has grown from a biotech into a leading biopharma and been included in the HSI," the company said. The company has been concurrently admitted to the Hang Seng China Enterprises Index, HSCEI, and the Hang Seng ESG Enhanced Index.